Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity, Part 1

被引:16
作者
Herold, Franciszek [1 ]
Chodkowski, Andrzej [1 ]
Izbicki, Lukasz [1 ]
Krol, Marek [1 ]
Kleps, Jerzy [1 ]
Turlo, Jadwiga [1 ]
Nowak, Gabriel [2 ,3 ]
Stachowicz, Katarzyna [2 ]
Dybala, Malgorzata [3 ]
Siwek, Agata [3 ]
机构
[1] Med Univ Warsaw, Fac Pharm, Dept Drug Technol, PL-02097 Warsaw, Poland
[2] Polish Acad Sci, Inst Pharmacol, PL-31343 Krakow, Poland
[3] Jagiellonian Univ, Coll Med, Dept Cytobiol & Histochem, PL-30688 Krakow, Poland
关键词
Antidepressants; Depression; 5-HT1A/5-HT-T dual activity; Pyrido[1,2-c]pyrimidines; RECEPTOR AGONISTS; ANTIDEPRESSANTS; PHARMACOLOGY; DERIVATIVES; INHIBITION; PROFILE; MICE;
D O I
10.1016/j.ejmech.2008.09.021
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of new derivatives of 4-aryl-pyrido[1,2-c]pyrimidine containing the 3-(4-piperidyl)-1H-indole residue or its 5-methoxy derivative were synthesized. They were characterized (i) in vitro by binding to 5-HT1A receptors and 5-HT transporter proteins in rat brain cortex membranes and (ii) in vivo in the mouse by induced hypothermia and forced swimming models for antagonist/agonist activity against the 5-HT1A autoreceptors and postsynaptic 5-HT1A receptors, respectively. Structure activity relationship evaluation indicated that the presence of the 3-(4-piperidyl)-1H-indole residue and ortho- or para-substituents with -F or -CH3 groups in the aryl ring as well as an unsubstituted aryl in the 4-aryl-pyrido[1,2-c]pyrimidine moiety promoted low K-i values for both receptors. In contrast, the presence of a 5-methoxy-3-(4-piperidyl)-1H-indole methoxy-3-(4-piperidyl)-1H-indole residue as well as -CI or -OCH3 substituents at the para position markedly reduced the receptor affinity. (c) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1710 / 1717
页数:8
相关论文
共 28 条
[1]   Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists [J].
Artigas, F ;
Romero, L ;
deMontigny, C ;
Blier, P .
TRENDS IN NEUROSCIENCES, 1996, 19 (09) :378-383
[2]  
ARTIGAS F, 1994, ARCH GEN PSYCHIAT, V51, P248
[3]   How does pindolol improve antidepressant action? [J].
Artigas, F ;
Celada, P ;
Laruelle, M ;
Adell, A .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (05) :224-228
[4]   5-HT AND ANTIDEPRESSANTS - NEW VIEWS FROM MICRODIALYSIS STUDIES [J].
ARTIGAS, F .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1993, 14 (07) :262-262
[5]  
BLIER P, 1990, J CLIN PSYCHIAT, V51, P14
[6]  
Briner K, 1998, CURR PHARM DESIGN, V4, P291
[7]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[8]  
Feighner JP, 1999, J CLIN PSYCHIAT, V60, P4
[9]   A PHARMACOLOGICAL PROFILE OF THE SELECTIVE SILENT 5-HT1A RECEPTOR ANTAGONIST, WAY-100635 [J].
FORSTER, EA ;
CLIFFE, IA ;
BILL, DJ ;
DOVER, GM ;
JONES, D ;
REILLY, Y ;
FLETCHER, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 281 (01) :81-88
[10]   THE PHARMACOLOGY OF THE HYPOTHERMIC RESPONSE IN MICE TO 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN (8-OH-DPAT) - A MODEL OF PRESYNAPTIC 5-HT1 FUNCTION [J].
GOODWIN, GM ;
DESOUZA, RJ ;
GREEN, AR .
NEUROPHARMACOLOGY, 1985, 24 (12) :1187-1194